E320 Bradlay Pryde, COO and Co-Founder at OneThree Biotech

Today's guest is Bradlay Pryde, COO and Co-Founder at OneThree Biotech in New York. Founded in 2018, OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven AI. Their technology was built in a lab setting, allowing them to engineer their methodologies around real-world results.

While working with major biotech and pharma partners, OneThree Biotech validated their predictions through work in target discovery, compound and combination therapy identification, toxicity prediction, biomarker selection and much more. Their predictions have been validated with partners such as AstraZeneca and Jubilant. For example, they predicted the top indication and mechanism of action for Oncoceutics asset ONC201 which was subsequently validated in a Phase II trial.

In the episode, Bradlay will discuss:

The work he does with OneThree Biotech,

The journey of building up the company from scratch,

How the pandemic impacted the business,

Interesting projects and milestones they are working towards,

How they attract top talent &

What excites him for the future at OneThree Biotech